Companies: 10,795·Total market cap: $144.5T
Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTENASDAQHealthcare
$2.65
$-0.01(-0.38%)
Market Cap$124990960
P/E Ratio—
52W High$7.185
52W Low$1.04
SEC Filings

Kinnate Biopharma Inc. (KNTE) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001797768 · KNTE · NASDAQ · as of Jun 10, 2026

Filing snapshot

250
Total Filings
SC 13G/A
Latest Form
2024-11-13
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001797768 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2024-03-28
Fiscal Year End
Mar 28, 2024
Accession No.
0001140361-24-016132
Primary Document
ef20015360_10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001797768 · Accession 0001140361-24-016132

Latest Key Filings

10-QQuarterly Report
10-Q
2023-11-09
View 10-Q on SEC
8-KCurrent Report
8-K
2024-04-03Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-11-13
View
15-12G15-12G
15-12G
2024-04-17
View
SC 13D/ASC 13D/A
AMENDMENT NO. 6
2024-04-05
View
S-8 POSS-8 POS
S-8 POS
2024-04-03
View
S-8 POSS-8 POS
S-8 POS
2024-04-03
View
S-8 POSS-8 POS
S-8 POS
2024-04-03
View
POSASRPOSASR
POSASR
2024-04-03
View
8-KCurrent Report
8-K
2024-04-03
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-04-03
View
25-NSE25-NSE
25-NSE
2024-04-03
View
SC TO-T/ASC TO-T/A
SC TO-T/A
2024-04-03
View
10-KAnnual Report
10-K
2024-03-28
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-03-22
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-03-19
View
SC TO-T/ASC TO-T/A
SC TO-T/A
2024-03-19
View
Showing 1–15 of 157 filingsForm 4 / 144 hidden· 250 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001797768  |  Exchange: NASDAQ · Healthcare

Kinnate Biopharma Inc. (NASDAQ: KNTE) has submitted 250 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001797768, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Kinnate Biopharma Inc.'s most comprehensive regulatory disclosure. The most recent Kinnate Biopharma Inc. 10-K was filed on 2024-03-28 for fiscal year ending 2024. Historical KNTE 10-K annual reports are available from 2019 through 2024.

Investors researching Kinnate Biopharma Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10
Related Companies SEC Filings — Healthcare
TRML SEC Filings →PRDS SEC Filings →NGM SEC Filings →SESN SEC Filings →PRTK SEC Filings →DBTX SEC Filings →GRAY SEC Filings →AADI SEC Filings →
→ KNTE Financials→ KNTE Earnings→ KNTE Insider Trades

Frequently Asked Questions

KNTE SEC Filings · 8 questions

Kinnate Biopharma Inc. (KNTE) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 250 filings and access original documents at no cost. Kinnate Biopharma Inc.'s CIK is 0001797768.

KNTE SEC filingsKinnate Biopharma Inc. SEC documentsfind KNTE 10-K